Search results
Our goal is clear: we want to provide better medicines for patients worldwide. Our toolbox includes a broad range of drug classes and platform technologies including mRNA-based therapies, cell therapies, small molecules as well as antibodies and other protein-based therapies.
- Our Senior Team
Prof. Pedro L. Alonso, M.D., Ph.D., joined BioNTech in 2023...
- Open Positions
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Vision & Mission
A global immunotherapy powerhouse. We aim to bring novel...
- Newsroom
First BioNTainer arrives in Rwanda - Sierk Poetting and...
- Therapeutic Areas
BioNTech initiated a clinical phase 1 trial for an...
- History
The Pfizer-BioNTech COVID-19 vaccine is the first vaccine to...
- Pipeline
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Collaborators
Autolus Therapeutics. In February 2024, we entered into a...
- Our Senior Team
BioNTech SE (/ b iː ˈ ɒ n t ɛ k / bee-ON-tek; or / b aɪ ˈ ɒ n t ɛ k / bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
Vision & Mission. A transatlantic leader in individualized neoantigen-targeted T cell therapies. Based in Cambridge, MA, BioNTech US serves as BioNTech’s North American headquarters and is an important part of our global effort to pioneer the development of next-generation immuno-oncology therapies.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
Aug 23, 2021 · August 23, 2021. Español. Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be...
Aug 18, 2022 · The Pfizer BioNTech vaccine against COVID-19 has very high efficacy against severe disease and moderate efficacy against symptomatic SARS-CoV-2 infection. What is the recommended dosage? For all persons aged 12 years and above, SAGE recommends two doses (30 µg, 0.3 ml each), 4-8 weeks apart given intramuscularly into the deltoid muscle.